Cargando…
Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020
BACKGROUND: In India, laboratory diagnosis of SARS – CoV-2 infection has been mostly based on real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Studies have shown that Viral titres peak within the first week of symptoms but may decline later hampering RT-PCR-based diagnostic strate...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140269/ https://www.ncbi.nlm.nih.gov/pubmed/34041197 http://dx.doi.org/10.4103/jfmpc.jfmpc_2015_20 |
_version_ | 1783696158604918784 |
---|---|
author | Sakalle, Salil Saroshe, Satish Shukla, Harish Mutha, Anita Vaze, Ameya Arora, Arpit Athotra, Aditya Ramaswamy, Sudarshan Jain, Arania Dhuria, Meera Patil, Anil D. Rai, Arvind Garg, Suneela Jain, Sudhir K. Bindal, Jyoti Singh, Sujeet K. |
author_facet | Sakalle, Salil Saroshe, Satish Shukla, Harish Mutha, Anita Vaze, Ameya Arora, Arpit Athotra, Aditya Ramaswamy, Sudarshan Jain, Arania Dhuria, Meera Patil, Anil D. Rai, Arvind Garg, Suneela Jain, Sudhir K. Bindal, Jyoti Singh, Sujeet K. |
author_sort | Sakalle, Salil |
collection | PubMed |
description | BACKGROUND: In India, laboratory diagnosis of SARS – CoV-2 infection has been mostly based on real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Studies have shown that Viral titres peak within the first week of symptoms but may decline later hampering RT-PCR-based diagnostic strategies. Exact estimate is difficult under high-risk screening strategy with evidences of having large number of asymptomatic cases. This has prompted a call for adoption of antibody testing as potential source of data. MATERIALS AND METHODS: A cross-sectional study with a sample size of 7000 was conducted for 15 days including all the 85 wards under Indore Municipal Corporation. Stratified Random Sampling was used to collect the samples. Trained teams collected basic sociodemographic information and serum samples which were tested for the presence of specific antibodies to COVID-19 using ICMR-Kavach IgG ELISA kits. The data collected was compiled and analysed using appropriate statistical software. RESULTS: Overall weighted seroprevalence of the study population was found to be 7.75%. The prevalence in males and females was comparable (7.91% vs 7.57%). Highest seropositivity (10.04%) was seen among individuals aged more than 60 years. Total number of infections in the population were estimated to be 2,03,160. Overall Case Infection Ratio was found to be 27.43. CONCLUSION: The current seroprevalence study provides information on proportion of the population exposed, but the correlation between presence and absence of antibodies is not a marker of total or partial immunity. It must also be noted that more than 90 percent of the population is still susceptible for COVID-19 infection. Hence, non-pharmaceutical interventions like respiratory hygiene, physical distancing, hand sanitization, usage of personal protective equipment such as masks and implementation of public health measures need to be continued. |
format | Online Article Text |
id | pubmed-8140269 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-81402692021-05-25 Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020 Sakalle, Salil Saroshe, Satish Shukla, Harish Mutha, Anita Vaze, Ameya Arora, Arpit Athotra, Aditya Ramaswamy, Sudarshan Jain, Arania Dhuria, Meera Patil, Anil D. Rai, Arvind Garg, Suneela Jain, Sudhir K. Bindal, Jyoti Singh, Sujeet K. J Family Med Prim Care Original Article BACKGROUND: In India, laboratory diagnosis of SARS – CoV-2 infection has been mostly based on real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Studies have shown that Viral titres peak within the first week of symptoms but may decline later hampering RT-PCR-based diagnostic strategies. Exact estimate is difficult under high-risk screening strategy with evidences of having large number of asymptomatic cases. This has prompted a call for adoption of antibody testing as potential source of data. MATERIALS AND METHODS: A cross-sectional study with a sample size of 7000 was conducted for 15 days including all the 85 wards under Indore Municipal Corporation. Stratified Random Sampling was used to collect the samples. Trained teams collected basic sociodemographic information and serum samples which were tested for the presence of specific antibodies to COVID-19 using ICMR-Kavach IgG ELISA kits. The data collected was compiled and analysed using appropriate statistical software. RESULTS: Overall weighted seroprevalence of the study population was found to be 7.75%. The prevalence in males and females was comparable (7.91% vs 7.57%). Highest seropositivity (10.04%) was seen among individuals aged more than 60 years. Total number of infections in the population were estimated to be 2,03,160. Overall Case Infection Ratio was found to be 27.43. CONCLUSION: The current seroprevalence study provides information on proportion of the population exposed, but the correlation between presence and absence of antibodies is not a marker of total or partial immunity. It must also be noted that more than 90 percent of the population is still susceptible for COVID-19 infection. Hence, non-pharmaceutical interventions like respiratory hygiene, physical distancing, hand sanitization, usage of personal protective equipment such as masks and implementation of public health measures need to be continued. Wolters Kluwer - Medknow 2021-03 2021-04-08 /pmc/articles/PMC8140269/ /pubmed/34041197 http://dx.doi.org/10.4103/jfmpc.jfmpc_2015_20 Text en Copyright: © 2021 Journal of Family Medicine and Primary Care https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Sakalle, Salil Saroshe, Satish Shukla, Harish Mutha, Anita Vaze, Ameya Arora, Arpit Athotra, Aditya Ramaswamy, Sudarshan Jain, Arania Dhuria, Meera Patil, Anil D. Rai, Arvind Garg, Suneela Jain, Sudhir K. Bindal, Jyoti Singh, Sujeet K. Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020 |
title | Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020 |
title_full | Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020 |
title_fullStr | Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020 |
title_full_unstemmed | Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020 |
title_short | Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020 |
title_sort | seroprevalence of anti-sars-cov-2 antibodies in indore, madhya pradesh: a community-based cross-sectional study, august 2020 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140269/ https://www.ncbi.nlm.nih.gov/pubmed/34041197 http://dx.doi.org/10.4103/jfmpc.jfmpc_2015_20 |
work_keys_str_mv | AT sakallesalil seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020 AT saroshesatish seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020 AT shuklaharish seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020 AT muthaanita seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020 AT vazeameya seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020 AT aroraarpit seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020 AT athotraaditya seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020 AT ramaswamysudarshan seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020 AT jainarania seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020 AT dhuriameera seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020 AT patilanild seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020 AT raiarvind seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020 AT gargsuneela seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020 AT jainsudhirk seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020 AT bindaljyoti seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020 AT singhsujeetk seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020 |